EUVIMEDEUVIMED entdecken
Crossref

The profile and clinical predicting effect of non-rash dermatologic toxicity related to targeted therapy in stage-IV non-small cell lung cancer patients

Yanmei Peng, Collin M Costello, Zhaoheng Liu, Ashok V Kumar, Zhong Gu, Nikhila Kosuru, Jason A Wampfler, Pedro A Reck Dos Santos, Jonathan D'Cunha, Vinicius Ernani, Ping Yang

BioScience Trends · 2025

DOI: 10.5582/bst.2024.01424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioScience Trends, 2025. Verfasst von Yanmei Peng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Fangshan Hospital Beijing University of Chinese Medicine, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Exanthema, Molecular Targeted Therapy. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dermatologic toxicities associated with targeted therapies may impact drug intolerance and predict drug response, among which rash is most frequently reported and well delineated. However, the profile and effect of non-rash dermatologic toxicity are not fully understood. We identified stage-IV non-small cell lung cancer patients diagnosed at Mayo Clinic in 2006-2019 and systematically analyzed demographics, targeted agents, toxicity, response, and survival outcomes of patients who received targeted therapy. Five toxicity subgroups-none, only non-rash dermatologic, concurrent non-rash and rash (concurrent) dermatologic, only rash, and others-were compared; multivariable survival analyses employed Cox Proportional Hazard models. This study included 533 patients who had taken targeted therapies: 36 (6.8%) had no toxicity, 26 (4.9%) only non-rash dermatologic, 193 (36.2%) only rash, 134 (25.1%) concurrent dermatologic, 144 (27.0%) other toxicities. Non-rash dermatologic toxicities predominately included xerosis (12.8%), pruritus (8.5%), paronychia (7.0%). Rash was the most frequent (59.4%) and the earliest occurring (21 median onset days [MOD]) dermatologic toxicity; paronychia was the latest (69 MOD) occurring. In 329 epidermal growth factor receptor inhibitors-treated patients with dermatologic toxicity, mild toxicity occurred the most frequently in patients with only non-rash (81.8%), then those with only rash (64.8%), and the least in the concurrent (50.4%, P=0.013). Patients with concurrent dermatologic toxicities had a significantly higher response rate (67.9%) than those with only non-rash (53.8%) or only rash (41.1%, p < 0.001). Multivariable analysis demonstrated concurrent dermatologic toxicity independently predicted a lower risk of death (harzard ratio [HR] 0.48 [0.30-0.77], p < 0.001). Compared to rash, non-rash dermatologic toxicity might be a stronger predictor of better treatment response and longer survival in patients who received targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsExanthemaMolecular Targeted TherapyAntineoplastic AgentsHumansMaleFemaleMiddle AgedAgedNeoplasm StagingRetrospective StudiesAged, 80 and overAdult

Stichwörter der Autor:innen

dermatologic toxicitylung cancernon-rashsurvivaltarget therapy

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Oncology, Fangshan Hospital Beijing University of Chinese Medicine, Beijing, China.
  • Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, AZ, USA.
  • Department of Dermatology, Mayo Clinic, AZ, USA.
  • School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
  • Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, MN, USA.
  • Division of Thoracic Surgery, Mayo Clinic, AZ, United States of America.

Zitieren

APA

Peng, Y., Costello, C. M., Liu, Z., Kumar, A. V., Gu, Z., Kosuru, N., Wampfler, J. A., Reck Dos Santos, P. A., D'Cunha, J., Ernani, V., & Yang, P. (2025). The profile and clinical predicting effect of non-rash dermatologic toxicity related to targeted therapy in stage-IV non-small cell lung cancer patients. BioScience Trends. https://doi.org/10.5582/bst.2024.01424

Vancouver

Peng Y, Costello CM, Liu Z, Kumar AV, Gu Z, Kosuru N, et al. The profile and clinical predicting effect of non-rash dermatologic toxicity related to targeted therapy in stage-IV non-small cell lung cancer patients. BioScience Trends. 2025. doi:10.5582/bst.2024.01424

BibTeX
@article{Peng2025,
  author = {Peng, Yanmei and Costello, Collin M and Liu, Zhaoheng and Kumar, Ashok V and Gu, Zhong and Kosuru, Nikhila and Wampfler, Jason A and Reck Dos Santos, Pedro A and D'Cunha, Jonathan and Ernani, Vinicius and Yang, Ping},
  title = {The profile and clinical predicting effect of non-rash dermatologic toxicity related to targeted therapy in stage-IV non-small cell lung cancer patients},
  journal = {BioScience Trends},
  year = {2025},
  doi = {10.5582/bst.2024.01424}
}
Kostenlos starten →